Valuation: Medivir AB

Market Cap 1.09B 112M 97.15M 91.69M 83.18M 156M 10.75B 157M 422M 5.45B 421M 412M 17.33B P/E 2026 *
-11.6x
P/E 2027 * -8.11x
Enterprise Value 999M 102M 88.64M 83.65M 75.88M 142M 9.8B 143M 385M 4.97B 384M 376M 15.81B EV / Sales 2026 *
217x
EV / Sales 2027 * 6.4x
Free-Float
63.91%
Yield 2026 *
-
Yield 2027 * -
1 day-2.75%
1 week-5.94%
Current month-9.31%
1 month+1.96%
3 months+2.55%
6 months-27.08%
Current year+333.25%
1 week 1.76
Extreme 1.764
1.98
1 month 1.64
Extreme 1.636
2.16
Current year 0.39
Extreme 0.392
2.88
1 year 0.34
Extreme 0.34
2.88
3 years 0.34
Extreme 0.34
8.25
5 years 0.34
Extreme 0.34
11.84
10 years 0.34
Extreme 0.34
102
Manager TitleAgeSince
Chief Executive Officer 55 2022-01-23
Director of Finance/CFO - 2026-03-22
Chief Tech/Sci/R&D Officer 60 2023-02-19
Director TitleAgeSince
Chairman 76 2021-05-04
Director/Board Member 70 2018-05-02
Director/Board Member 47 2021-05-04
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/26
Hallberg Management AB
BuyCompany 6,097,560 0.9868%
6/18/26 Buy

Chief Financial Officer

18,000 0.0033%
12/5/25 Buy 90,000 0.0802%
Change 5-day change 1-year change 3-year change Capi.($)
-2.64%-5.94%-7.03%-77.78% 116M
+5.04%+3.27%+50.62%+105.43% 66.93B
+1.64%-2.89%+34.67%+80.49% 61.97B
-3.18%-0.78%-14.14%+376.43% 28.26B
+4.55%-0.08%+34.70%+17.28% 24.59B
+2.20%-4.72%+2.19%-12.71% 24.3B
+1.15%-2.26%+17.56%-16.53% 19.41B
-7.03%-9.16%+161.91%+303.00% 16.77B
+3.44%-1.68%-5.00%+541.17% 14.18B
+4.96%+4.63%-2.75%+879.79% 14B
Average +1.00%-3.89%+27.27%+219.66% 27.05B
Weighted average by Cap. +1.98%-2.84%+33.23%+175.73%

Financials

2026 *2027 *
Net sales 4.6M 471K 408K 385K 349K 655K 45.15M 660K 1.77M 22.9M 1.77M 1.73M 72.81M 148M 15.21M 13.18M 12.43M 11.28M 21.16M 1.46B 21.31M 57.22M 739M 57.11M 55.85M 2.35B
Net income -72.78M -7.45M -6.46M -6.09M -5.53M -10.37M -714M -10.45M -28.04M -362M -27.99M -27.37M -1.15B 33.53M 3.43M 2.98M 2.81M 2.55M 4.78M 329M 4.81M 12.92M 167M 12.9M 12.61M 531M
Net Debt -96M -9.83M -8.52M -8.04M -7.29M -13.68M -942M -13.78M -36.99M -478M -36.92M -36.11M -1.52B -145M -14.85M -12.87M -12.14M -11.01M -20.66M -1.42B -20.81M -55.87M -722M -55.77M -54.54M -2.3B
Logo Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Employees
6
Date Price Change Volume
26-09-14 SEK 1.772 -2.64% 853,659
26-09-11 SEK 1.820 -1.09% 845,849
26-09-10 SEK 1.840 -2.95% 2,073,460
26-09-09 SEK 1.896 +0.85% 2,078,722
26-09-08 SEK 1.880 -1.57% 713,097
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.772SEK
Average target price
5.768SEK
Spread / Average Target
+225.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MVIR B Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!